Delivery Order SPE2DB24D2018-SPE2DB25FWWP5
- Not listed
- The Defense Logistics Agency awarded a $2,205.54 delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injectors on August 13, 2025, with completion targeted for August 14, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy product delivered via auto-injection, representing part of the...
- The Defense Logistics Agency awarded a delivery order valued at $1,248.08 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injectors on August 22, 2025, with completion targeted for August 25, 2025. This firm fixed-price contract represents a non-set-aside competitive award and will be fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy product delivered via auto-injector, addressing pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,544.96 to supply Xyosted 50 mg/0.5 mL auto-injector units. The contract, awarded on June 2, 2025, with an ultimate completion date of June 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will occur at the vendor's corporate office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy auto-injector prescribed for hormone...
- The Defense Logistics Agency awarded a $1,937.56 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector supplies. This competitively awarded, non-set-aside contract was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy product delivered via auto-injector, supporting the military...
- The Defense Logistics Agency awarded a $1,629.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies on June 17, 2025, with completion scheduled for June 18, 2025. This delivery order was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Xyosted is a testosterone replacement therapy auto-injector used in military and veteran healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $1,204.42 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector units on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. XYOSTED is a testosterone replacement therapy medication delivered via auto-injector,...
- The Defense Logistics Agency awarded a delivery order valued at $1,308.93 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector units on July 21, 2025, with completion scheduled for July 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. XYOSTED is a testosterone replacement therapy product administered via auto-injector, supporting the Defense Health...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,646.02 to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units on July 25, 2025, with completion scheduled for July 28, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a competitive award under open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xyosted is a...
- The Defense Logistics Agency awarded a $1,436.03 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector units. The contract is a firm fixed-price delivery order with an ultimate completion date of June 2, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor specializing in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector supplies, with a ceiling value of $1,314.73 under a firm fixed-price arrangement. The contract was competitively awarded without set-aside provisions and is due for completion by September 9, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB24D2018Indefinite Delivery Contract
- SPE2DB24D2018-SPE2DB25FWWP5Delivery Order
The Defense Logistics Agency awarded a $1,752.22 delivery order to AmerisourceBergen Drug Corp for Xyosted 50 mg/0.5 mL auto-injectors on September 5, 2025, with completion scheduled for September 8, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract and will be performed at the contractor's Conshohocken, Pennsylvania facility. Xyosted is a testosterone replacement therapy medication delivered via auto-injector, reflecting the Defense Logistics Agency's continued procurement of specialized pharmaceutical products for military healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen maintains an extensive portfolio supplying the Defense Health Agency and other government healthcare systems with brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities. The company's selection for this order underscores its established capability to fulfill federal pharmaceutical supply requirements through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 9/5/25 |